Archives

  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • GLP-1 (9-36) amide: Precision Antagonist for Human GLP-1 ...

    2026-02-16

    GLP-1 (9-36) amide: Precision Antagonist for Human GLP-1 Receptor Studies

    Executive Summary: GLP-1 (9-36) amide is a selective peptide antagonist at the human GLP-1 receptor, enabling precise interrogation of incretin hormone signaling (Chepurny et al., 2019). The product, manufactured by APExBIO (SKU B5404), is supplied as a white lyophilized solid with 100% purity verified by HPLC and mass spectrometry (APExBIO product page). It is insoluble in DMSO, ethanol, and water, necessitating specialized solubilization protocols. GLP-1 (9-36) amide provides a benchmark tool for dissecting the complexity of GLP-1 receptor signaling in metabolic, pharmacological, and type 2 diabetes research. Recent high-throughput FRET studies have clarified its antagonist mechanism and selectivity profile (DOI:10.1074/jbc.RA118.005682).

    Biological Rationale

    GLP-1 (9-36) amide is a truncated peptide derivative of the endogenous incretin hormone GLP-1. It lacks N-terminal residues critical for receptor activation, conferring antagonist properties at the human GLP-1 receptor (Chepurny et al., 2019). GLP-1 receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) expressed primarily on pancreatic β-cells, where it mediates glucose-dependent insulin secretion (GLP-1 (9-36) amide: Optimizing GLP-1 Receptor Antagonist). Research on GLP-1 (9-36) amide enables dissection of GLP-1R-specific signaling, separating it from overlapping actions of glucagon and related peptides. This specificity is vital for studies on metabolic regulation, type 2 diabetes, and incretin hormone pathways.

    Mechanism of Action of GLP-1 (9-36) amide

    GLP-1 (9-36) amide acts as a competitive antagonist at the human GLP-1 receptor. It binds the orthosteric ligand-binding pocket, blocking GLP-1 and related agonists from inducing cAMP responses in target cells (DOI:10.1074/jbc.RA118.005682). In high-throughput FRET assays, GLP-1 (9-36) amide (and related antagonists such as exendin(9-39)) efficiently inhibited GLP-1-induced cAMP production in INS-1 832/13 β-cells at nanomolar concentrations. Its selectivity profile ensures minimal cross-reactivity with glucagon or GIP receptors under standard assay conditions. The amide modification at the C-terminus enhances metabolic stability relative to non-amidated forms.

    Evidence & Benchmarks

    • GLP-1 (9-36) amide inhibits GLP-1-induced cAMP production in β-cells with an IC50 in the low nanomolar range (Chepurny et al., 2019).
    • Competitive antagonism was demonstrated using high-throughput FRET-based cAMP assays in INS-1 832/13 cells (DOI:10.1074/jbc.RA118.005682).
    • APExBIO’s GLP-1 (9-36) amide (SKU B5404) is supplied at >99% purity by HPLC and mass spectrometry verification (Product page).
    • The peptide is insoluble in water, DMSO, and ethanol, requiring specialized solubilization (see product datasheet for protocols) (APExBIO).
    • GLP-1 (9-36) amide does not significantly antagonize glucagon or GIP action at their cognate receptors at standard assay concentrations (DOI:10.1074/jbc.RA118.005682).

    This article extends the mechanistic analysis provided in "Reimagining GLP-1 Receptor Antagonism" by integrating new FRET-based selectivity benchmarking and workflow-specific insights.

    Applications, Limits & Misconceptions

    GLP-1 (9-36) amide is primarily used in:

    • GLP-1 receptor signaling research to delineate agonist versus antagonist mechanisms.
    • Metabolic regulation studies, including models of type 2 diabetes and incretin pathway analysis.
    • Pharmacological profiling of peptide antagonists in human and rodent β-cell lines.

    It is not suitable for in vivo studies requiring systemic exposure, due to rapid degradation and poor solubility in physiological solvents.

    Common Pitfalls or Misconceptions

    • Misconception: GLP-1 (9-36) amide is an agonist.
      Fact: It acts as a competitive antagonist at the GLP-1 receptor (DOI:10.1074/jbc.RA118.005682).
    • Pitfall: Assuming water solubility.
      Fact: The peptide is insoluble in water, DMSO, and ethanol, necessitating alternative solubilization strategies (APExBIO).
    • Misconception: Suitable for all species.
      Fact: Sequence specificity may limit cross-species applications; verify alignment with species of interest.
    • Pitfall: Long-term storage in solution.
      Fact: Instability in solution mandates prompt use after reconstitution and storage at -20°C desiccated (APExBIO).
    • Misconception: Broad GPCR antagonism.
      Fact: GLP-1 (9-36) amide does not significantly antagonize glucagon or GIP receptors at standard concentrations (DOI:10.1074/jbc.RA118.005682).

    This clarification updates the best-practices section of "GLP-1 (9-36) Amide: Precision Tool for GLP-1 Receptor Signal..." by emphasizing handling and selectivity boundaries.

    Workflow Integration & Parameters

    Handling: GLP-1 (9-36) amide should be stored lyophilized at -20°C in a desiccated environment. Use blue ice for shipping small molecules or dry ice for modified nucleotides. Reconstitute immediately before use; avoid repeated freeze-thaw cycles. Specialized solvents or buffer systems, as detailed in the product datasheet, are required for dissolution due to insolubility in water, DMSO, and ethanol (APExBIO).

    Assay Recommendations: Employ high-throughput FRET-based cAMP assays in GLP-1R-expressing cell lines (e.g., INS-1 832/13) for antagonist activity benchmarking. Use at nanomolar concentrations for optimal specificity and minimal off-target effects.

    Quality Control: Each lot from APExBIO is supplied with a Certificate of Analysis, HPLC purity (>99%), and mass spectrometry data. Refer to the Material Safety Data Sheet for laboratory safety compliance.

    This section clarifies workflow-specific troubleshooting strategies in "Redefining GLP-1 Receptor Antagonism: Mechanistic Insight..." by addressing solubilization and storage challenges unique to GLP-1 (9-36) amide.

    Conclusion & Outlook

    GLP-1 (9-36) amide (APExBIO, SKU B5404) stands as a gold-standard peptide antagonist for precise interrogation of GLP-1 receptor signaling. Its validated selectivity, robust documentation, and integration into high-throughput assay workflows make it indispensable for metabolic regulation and type 2 diabetes research (Chepurny et al., 2019). Future work may expand its application to multiplexed receptor studies and advanced pathway dissection in human and translational models.

    For detailed protocols, quality documentation, or to purchase, refer to the GLP-1 (9-36) amide product page.